Study: Cancer-related genetic testing is rare for women on Medicare

August 20, 2018 6:28 pm

By Health Day News

Testing for gene mutations linked to breast and ovarian cancer is rare among some Medicare patients who have the cancers and qualify for such tests, a new study finds.

Researchers analyzed data from 12 southeastern states … Read more

Genetic Screening Can Inform Women of Their Breast and Ovarian Cancer Risks

July 6, 2018 7:21 pm

One of the most unsettling aspects of cancer is the unknown.

There is the unknown of what is in store for you if you receive a diagnosis of cancer. But on a larger scale, we all

Read more

Busting Myths Surrounding Cancer and Genetic Testing

April 18, 2018 12:02 am

While only 5 percent to 10 percent of cancers are caused by an inherited gene mutation, genetic testing may benefit people with a strong history of family cancer, an expert in genetics suggests.

This is especially true in families with … Read more

FDA Approves Rubraca for Maintenance Ovarian Cancer Treatment

April 6, 2018 8:05 pm

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the … Read more

Could New Approach Stave Off Ovarian Cancer? Study May Tell

March 16, 2018 7:08 pm

Anna Hargrove learned she carries a genetic mutation that predisposes women toward breast and ovarian cancer at 27, which was no surprise given her family history.

Hargrove, cautious by nature, did what a lot of women with the mutation do: … Read more

FDA Approves 23andMe Cancer Test For BRCA Genes

March 12, 2018 8:33 pm

The home DNA testing company 23andMe has received approval from the US Food and Drug Administration (FDA) to test for three genetic mutations in two genes that you have probably heard of if you know who Angelina Jolie is, BRCA1 … Read more

Screening Beyond Those With Cancer History May Be More Effective

February 12, 2018 10:32 pm

As genetic testing becomes more accessible with advanced technology and decreased costs, population-based testing for breast and ovarian cancer may be more cost effective in the long run, according to study results published in Journal of the National Cancer InstituteRead more

BRCA1 Methylation Tied to Ovarian Cancer Risk

January 18, 2018 4:26 am

BRCA1 mutations are well-known to predispose to ovarian cancer risk. But now a new study, appearing in the Annals of Internal Medicine, suggests that methylation of normal BRCA1 genes might be a major ovarian cancer risk factor. In this Read more

Women with Ovarian Cancer Who May Benefit from Maintenance Treatment

January 15, 2018 6:18 pm

Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).

Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more

FDA Grants Priority Review for Rucaparib

December 28, 2017 8:08 pm

The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more

Fallopian Tube Removal May Help Prevent Most Common Ovarian Cancer

December 20, 2017 7:52 pm

A study published in October showed that high-grade serous ovarian carcinomas (HGSOC), which account for about 75 percent of ovarian cancers, originate with abnormal cells in the fallopian tubes an average of seven years before the disease develops. This understanding … Read more

Health Matters: Testing Your Genes for Cancer

December 12, 2017 12:21 am

Whether you’ve already been diagnosed, or you want to know your risk, health experts can test your DNA to determine your chances of developing cancer.

“The testing itself determines whether or not they have inherited this broken gene that could … Read more

Loss of Heterozygosity in BRCA Gene May Influence Survival in Breast and Ovarian Cancers

August 28, 2017 7:17 pm

Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance … Read more

How PARP Inhibitors Might Prove Useful In More Than Just BRCA Cancers

August 2, 2017 7:56 pm

PARP inhibitor Lynparza (olaparib) has been embraced by oncologists treating women with BRCA-mutant ovarian cancer, and the AstraZeneca drug is also showing promise in breast cancers that harbor the same mutations. But scientists led by the University of Pennsylvania believe … Read more

PARP Inhibitor Active in BRCA Subgroups

March 14, 2017 5:52 pm

Patients with relapsed BRCA-mutated ovarian cancer had a similar progression-free survival (PFS) with the PARP inhibitor rucaparib (Rubraca) regardless of the type of mutation, according to subgroup analyses of a prospective, multicenter trial.

Results showed a median PFS of … Read more

The Unbearably Slow Adoption of Genetic Cancer Tests

July 12, 2016 5:29 pm

Over the past 20 years, Nazneen Rahman has identified a steady stream of genes that influence the risk of breast, ovarian, and childhood cancers—work that has earned her scientific, popular, and even royal acclaim. But her latest accomplishment, and one … Read more